Quantum Biopharma (QNTM) Profit After Tax (2019 - 2026)

Quantum Biopharma has reported Profit After Tax for 8 years, with the latest figure at -$13.6 million in Q1 2026.

• Quarterly Profit After Tax fell 58.11% year-over-year to -$13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.2 million (down 76.97% YoY) and the FY2025 annual result came in at -$26.2 million, down 84.3% from the prior year.
• Profit After Tax declined to -$13.6 million in Q1 2026 per QNTM's latest filing, from -$3.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at $6.0 million in Q1 2022 and troughed at -$34.8 million in Q4 2023.
• A 5-year average of -$7.4 million and a median of -$5.5 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax slumped 266.54% in 2023, then surged 93.99% in 2024.
• Over 5 years, Profit After Tax stood at $6.0 million in 2022, then plunged by 682.21% to -$34.8 million in 2023, then soared by 93.99% to -$2.1 million in 2024, then plunged by 44.71% to -$3.0 million in 2025, then plunged by 348.06% to -$13.6 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$13.6 million, -$3.0 million, and -$5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.